{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:13:21Z","timestamp":1759342401370,"version":"3.37.3"},"reference-count":48,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Low\u2010density lipoprotein cholesterol (LDL\u2010C) has been extensively evaluated. Prospective cohort studies, randomized controlled trials, biology, pathophysiology, genetics, and Mendelian randomization studies, have clearly taught us that LDL\u2010C causes atherosclerotic cardiovascular disease. The newest class of drugs to lower LDL\u2010C, the proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies, have been found to safely reduce LDL\u2010C approximately 60% when added to high\u2010intensity statin therapy. Because their cost is much greater than that of the currently available agents, their value has been questioned. In late August, 2017, two groups assessed the value of this class of drugs looking at cost\u2010effectiveness; however, the Institute for Clinical and Economic Review and Fonarow and colleagues found disparate results when assessing PCSK9 valuation. Herein, we review the evolution of LDL\u2010C from hypothesis to fact, and then attempt to adjudicate the 2 models, shedding light on the complex modeling process. We find that models of cost\u2010effectiveness are helpful adjuncts to decision making, but that their conclusions depend on many assumptions. Ultimately, clinician judgment regarding their clinical benefit, balanced by some estimation of cost, may be more productive to target the right patients for whom the benefits can be well\u2010justified.<\/jats:p>","DOI":"10.1002\/clc.22924","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T12:56:44Z","timestamp":1520427404000},"page":"544-550","source":"Crossref","is-referenced-by-count":7,"title":["PCSK9 inhibitor valuation: A science\u2010based review of the two recent models"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-6607","authenticated-orcid":false,"given":"Seth J.","family":"Baum","sequence":"first","affiliation":[{"name":"Department of Integrated Medical Sciences Florida Atlantic University, Charles E. Schmidt College of Medicine  Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2013.12.004"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/128.2.439S"},{"issue":"4","key":"e_1_2_11_4_1","first-page":"113","article-title":"Nutrition classics. Archives of Internal Medicine, Volume 64, October 1939: Angina pectoris in hereditary xanthomatosis","volume":"45","author":"M\u00fcller C","year":"1987","journal-title":"Nutr Rev"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2007.03.003"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.86.484"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91755-8"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/330113a0"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu208"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20882"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702027200"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2007.04.004"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb1235"},{"key":"e_1_2_11_19_1","first-page":"1489","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"16","author":"Robinson JG","journal-title":"N Engl J Med."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-014-6523-z"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-121"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61770-X"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"e_1_2_11_26_1","unstructured":"PCSK9 inhibitors: payer dynamics. Symphony Health Solutions website.https:\/\/symphonyhealth.com\/wp\u2010content\/uploads\/2017\/03\/PCSK9\u2010Inhibitors\u2010Payer\u2010Dynamics\u2010Feb\u20102017.pdf. Accessed November 2017."},{"key":"e_1_2_11_27_1","unstructured":"BaumSJ ChenCC RanePB et al. Characteristics of patients approved and denied access in PCSK9i therapy by payers. Paper presented at: 66th Scientific Session of the American College of Cardiology; Washington DC; March 17\u201319 2017. Abstract 1258\u2010435."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.027705"},{"key":"e_1_2_11_29_1","unstructured":"KolataG. Study shows promise for expensive cholesterol drugs but they are still hard to obtain.New York Times. November 15 2016.https:\/\/www.nytimes.com\/2016\/11\/16\/health\/cholesterol\u2010drugs\u2010pcsk9\u2010inhibitors.html?_r=0. Accessed March 15 2017."},{"key":"e_1_2_11_30_1","unstructured":"BerkrotB. Amgen cholesterol drug reduces artery\u2010clogging plaque in study. Reuters website.http:\/\/www.reuters.com\/article\/us\u2010heartamgen\u2010cholesterol\u2010idUSKBN13A27Q. Published November 15 2016. Accessed March 15 2017."},{"key":"e_1_2_11_31_1","unstructured":"ChenC CortezM. Amgen's Repatha unclogs arteries in good sign for future sales.https:\/\/www.bloomberg.com\/news\/articles\/2016\u201011\u201015\/amgen\u2010s\u2010repatha\u2010unclogs\u2010arteries\u2010in\u2010good\u2010sign\u2010for\u2010future\u2010sales. Published November 15 2016. Accessed March 15 2017."},{"key":"e_1_2_11_32_1","unstructured":"ReddyS. Acholesterol drug tug\u2010of\u2010war. Wall Street Journal. June 20 2017.http:\/\/online.wsj.com\/public\/resources\/documents\/print\/WSJ_-A011-20170620.pdf. Accessed September 21 2017."},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22713"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701131"},{"key":"e_1_2_11_36_1","unstructured":"Institute for Clinical and Economic Review.https:\/\/icer-review.org. Accessed November 2017."},{"key":"e_1_2_11_37_1","unstructured":"Institute for Clinical and Economic Review.PCSK9 inhibitors: new evidence update.https:\/\/icer\u2010review.org\/material\/pcks9\u2010inhibitors\u2010neu. Accessed September 21 2017."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","unstructured":"World Health Organization Policy and practice: cost effectiveness thresholds pros and cons.http:\/\/www.who.int\/bulletin\/volumes\/94\/12\/15-164418\/en\/. Accessed September 21 2017.","DOI":"10.2471\/BLT.15.164418"},{"key":"e_1_2_11_41_1","first-page":"1","article-title":"Changes in the leading cause of death: recent patterns in heart disease and cancer mortality","volume":"254","author":"Heron M","year":"2016","journal-title":"NCHS Data Brief."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706444"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9924"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.77.11.1417"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2762"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22535"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1284078"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0492-6"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:41:32Z","timestamp":1695494492000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/clc.22924"],"URL":"https:\/\/doi.org\/10.1002\/clc.22924","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"type":"print","value":"0160-9289"},{"type":"electronic","value":"1932-8737"}],"subject":[],"published":{"date-parts":[[2018,3,7]]}}}